Altimmune, Inc.

Stocks

ALT

US02155H2004

Market Closed - Nasdaq 16:00:00 2026-09-18 EDT			5-day change	1st Jan Change
3.250 ^USD	+0.31%		-0.61%	-9.97%

08-12	Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Altimmune, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Transcript : Altimmune, Inc. - Special Call

Published on 07/28/2026 at 11:45 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, ladies and gentlemen, and welcome to the Altimmune RECLAIM Phase II Trial in AUD Topline Results Conference Call. [Operator Instructions]

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Altimmune, Inc.

08-12	Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Altimmune, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-03	Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH	MT
08-03	Altimmune, Inc. Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH	CI
07-28	Altimmune, Inc. - Special Call
07-28	Altimmune Announces Positive Topline Results from Reclaim Phase 2 Trial of Pemvidutide in Alcohol Use Disorder	CI
07-28	Altimmune's Investigational Alcohol Use Disorder Drug Meets Primary Endpoint in Phase 2 Study	MT
07-28	Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide	DJ
07-28	Altimmune drug cuts heavy drinking in mid-stage trial for alcohol use disorder	RE
07-21	Certain Stock Options of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.	CI
07-21	Certain Common Stock of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.	CI
07-21	Certain Pre-Funded Warrants of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.	CI
07-21	Certain Restricted Stock Units of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.	CI
07-07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-29	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark	CI

Chart Altimmune, Inc.

Duration

Period

ALT: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data

Ratings

More Ratings

EPS Estimates

Revisions to estimates